Ptc Therapeutics (PTCT) Income towards Parent Company (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Income towards Parent Company of $83.5 million for Q2 2026, up 228.75% year-over-year from $25.4 million in Q2 2025, and up 3072.45% quarter-over-quarter from -$2.8 million in Q1 2026.
Ptc Therapeutics (PTCT) Income towards Parent Company (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Income towards Parent Company history runs 15 years deep, the most recent figure standing at $83.5 million for Q2 2026.
- In Q2 2026, Income towards Parent Company rose 228.75% year-over-year to $83.5 million; the TTM figure through Jun 2026 stood at $382.5 million (up 4.26% YoY), while the FY2025 annual figure was $1.1 billion, up 276.39% from the prior year.
- Income towards Parent Company for Q2 2026 stood at $83.5 million, up from -$2.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was $866.6 million in Q1 2025, with the low at -$328.2 million in Q4 2024.
- The 5-year median for Income towards Parent Company is -$108.0 million (2022), against an average of -$40.0 million.
- The sharpest annual moves came in 2025 and 2026: Income towards Parent Company surged 1046.28% in 2025, then sank 100.32% in 2026.
- Ptc Therapeutics' Income towards Parent Company stood at -$174.5 million in 2022, then sank by 40.05% to -$244.4 million in 2023, then sank by 34.27% to -$328.2 million in 2024, then surged by 187.12% to $285.9 million in 2025, then plunged by 70.8% to $83.5 million in 2026.
- Business Quant data shows PTCT's Income towards Parent Company at $83.5 million in Q2 2026, -$2.8 million in Q1 2026, and $285.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.50 Mn |
| Mar 31, 2026 | -2.81 Mn |
| Dec 31, 2025 | -125.39 Mn |
| Sep 30, 2025 | 15.90 Mn |
| Jun 30, 2025 | -64.85 Mn |
| Mar 31, 2025 | 866.56 Mn |
| Dec 31, 2024 | 506.30 Mn |
| Sep 30, 2024 | -106.65 Mn |
| Jun 30, 2024 | -99.18 Mn |
| Mar 31, 2024 | -91.58 Mn |
| Dec 31, 2023 | -286.71 Mn |
| Sep 30, 2023 | -132.97 Mn |
| Jun 30, 2023 | -198.88 Mn |
| Mar 31, 2023 | -138.96 Mn |
| Dec 31, 2022 | -207.22 Mn |
| Sep 30, 2022 | -109.32 Mn |
| Jun 30, 2022 | -152.09 Mn |
| Mar 31, 2022 | -126.73 Mn |
| Dec 31, 2021 | -139.04 Mn |
| Sep 30, 2021 | -133.62 Mn |